National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
NCT Number: NCT00001413
The purpose of this study is to examine calcium absorption and bone mineral density in women with depression.
Research indicates that pre-menopausal women with depression have significantly lower bone mineral density (BMD) than pre-menopausal women without depression. Although the mechanisms of BMD loss are unclear, researchers believe that individuals with depression have impaired calcium absorption. However, it is unknown whether the abnormal absorption is a result of depression or a side effect of the drugs used to treat it. This study will compare calcium absorption in women with depression and in healthy women without depression.
Participants in this study will be given two non-radioactive calcium isotopes. One can be taken by mouth and the other must be injected. Participants will have the level of isotopes in their urine measured to estimate true fractional calcium absorption (TFCA). Participants may also have a dual X-ray absorptiometry (DEXA) scan to measure total body adiposity and lean body mass.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Bethesda, Maryland, 20892, United States
Osteoporosis is a condition that is underdiagnosed and undertreated, and often goes unnoticed until a fragility fracture occurs after many years of progressive loss of bone quality. Risk factors for osteoporosis include glucocorticoid excess and a pro-inflammatory state, both of which we and others have observed in a substantial proportion of patients with Major Depressive Disorder.
We have found statistically and clinically significant reductions in bone mineral density (BMD) in a group of 24 depressed but otherwise healthy pre-menopausal women, as compared to 24 healthy, closely matched controls. The difference was significant at several trabecular bone sites (e.g., 13.6% at the femoral neck, 13.6% at the Ward's triangle, and 10.8% at the trochanter). Epidemiological studies indicate that losses in trabecular bone mineral density of these magnitudes are associated with an increased lifetime risk for fracture up to 50%.
Although the mechanism(s) of the lower bone mineral density in our patients with past or current depression has not yet been elucidated, these subjects showed significantly higher 24-hour urinary free cortisol excretion than their matched controls. However, the extent of the lower bone mineral density in women with past or current depression cannot be accounted for strictly on the basis of hypercortisolism alone, but is likely to require other hormonal or biochemical factors as well.
Preliminary data in subjects recruited from a large study of mothers with or without mood disorders and their offspring indicate that a disproportionate number of young adult offspring of mothers with Major Depressive Disorder show reduced BMD, 2/3 of whom had not yet manifested clinical signs or symptoms of mood disorder.
In the light of the fact that major depression affects between 5% and 9% of the female population, the depression-associated lower bone mineral density potentially predisposes millions of women to enhanced susceptibility to osteoporosis. We therefore wish to continue our assessment of bone mineral density in subjects with past or current depression to further document the incidence of lower bone mineral density in a larger series. We also wish to identify subjects with past or present depression who have reduced bone mineral density to offer them the possibility of participating in other studies designed to clarify pathophysiologic mechanisms involved in low bone mineral density, identify any clinical characteristics of depressive illness that may predict increased risk of osteopenia or osteoporosis, examine the association of low BMD with other endocrine and metabolic disturbances seen in depressive illness, and to identify those who may require therapeutic intervention.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
-
Inclusion criteria
A history of current or past major depression of at least four months duration, or a history of two or more brief depressive episodes will be the primary criterion for inclusion.
Patients with Bipolar Disorder will be eligible if they meet the depressive episode criterion.
No specific inclusion criteria are set for normal volunteers.
Exclusion criteria
DEPRESSED SUBJECTS:
Pregnant women will not be eligible to participate.
Known medical causes of osteoporosis, other than depression.
Current or past history of eating disorders, or schizophrenia, as per DSM-IV.
Chronic use of oral or parenteral steroids (daily use for 3 months or longer).
HEALTHY SUBJECTS:
Pregnant women will not be eligible to participate.
Known medical causes of osteoporosis.
Any history of DSM-IV diagnosis, including depression, eating disorders, and alcohol or drug abuse.
History or current evidence of any significant clinical or laboratory abnormalities.
National Institute of Mental Health (NIMH)
Nih
Bone Mineral Density in Patients With Major Depression With Melancholic and Atypical Features: Relation to Stress-System Neurohormonal Function
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00006180
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsNCT03898297
Behavior, Behavioral Symptoms
New Haven, Connecticut, United States
View Trial DetailsNCT06570369
Behavior, Behavioral Symptoms
Garden Grove, California, United States
View Trial DetailsNCT00060736
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial Details